logo-loader
viewImugene Ltd

Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'

Imugene Limited’s (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong tells Proactive's Andrew Scott she's delighted with what the interim data has revealed in their ongoing randomised Phase 2 study of HER-Vaxx in gastric cancer. It's shown positive overall survival with a Hazard Ratio of 0.418. The median overall survival for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8 months in patients treated with chemotherapy alone. Chong says they're now assessing how best to take development of the drug forward.

Quick facts: Imugene Ltd

Price: 0.115 AUD

ASX:IMU
Market: ASX
Market Cap: $545.21 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene CEO says PD1-Vaxx could be 'paradigm shift' in oncology

Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong speaks to Proactive's Andrew Scott following the news they've dosed the first patient in a Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, in Melbourne, Australia. The trial is recruiting patients with non-small...

on 1/12/20

2 min read